Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PARP1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009009214 | Thyroid | ATC | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 120/6293 | 256/18723 | 6.62e-06 | 6.85e-05 | 120 |
GO:000628211 | Thyroid | ATC | regulation of DNA repair | 68/6293 | 130/18723 | 8.19e-06 | 8.27e-05 | 68 |
GO:000914527 | Thyroid | ATC | purine nucleoside triphosphate biosynthetic process | 41/6293 | 69/18723 | 9.68e-06 | 9.67e-05 | 41 |
GO:000915225 | Thyroid | ATC | purine ribonucleotide biosynthetic process | 84/6293 | 169/18723 | 1.05e-05 | 1.04e-04 | 84 |
GO:0010038210 | Thyroid | ATC | response to metal ion | 165/6293 | 373/18723 | 1.07e-05 | 1.05e-04 | 165 |
GO:003314316 | Thyroid | ATC | regulation of intracellular steroid hormone receptor signaling pathway | 43/6293 | 74/18723 | 1.30e-05 | 1.25e-04 | 43 |
GO:1904356110 | Thyroid | ATC | regulation of telomere maintenance via telomere lengthening | 37/6293 | 61/18723 | 1.35e-05 | 1.29e-04 | 37 |
GO:004639025 | Thyroid | ATC | ribose phosphate biosynthetic process | 92/6293 | 190/18723 | 1.57e-05 | 1.46e-04 | 92 |
GO:000920627 | Thyroid | ATC | purine ribonucleoside triphosphate biosynthetic process | 40/6293 | 68/18723 | 1.74e-05 | 1.59e-04 | 40 |
GO:000926025 | Thyroid | ATC | ribonucleotide biosynthetic process | 88/6293 | 182/18723 | 2.55e-05 | 2.20e-04 | 88 |
GO:001033217 | Thyroid | ATC | response to gamma radiation | 34/6293 | 56/18723 | 2.92e-05 | 2.45e-04 | 34 |
GO:000914227 | Thyroid | ATC | nucleoside triphosphate biosynthetic process | 47/6293 | 85/18723 | 3.16e-05 | 2.63e-04 | 47 |
GO:000675426 | Thyroid | ATC | ATP biosynthetic process | 34/6293 | 57/18723 | 4.91e-05 | 3.90e-04 | 34 |
GO:000283123 | Thyroid | ATC | regulation of response to biotic stimulus | 144/6293 | 327/18723 | 4.94e-05 | 3.91e-04 | 144 |
GO:000920126 | Thyroid | ATC | ribonucleoside triphosphate biosynthetic process | 41/6293 | 74/18723 | 9.32e-05 | 6.84e-04 | 41 |
GO:003220016 | Thyroid | ATC | telomere organization | 76/6293 | 159/18723 | 1.40e-04 | 9.75e-04 | 76 |
GO:000941613 | Thyroid | ATC | response to light stimulus | 139/6293 | 320/18723 | 1.42e-04 | 9.88e-04 | 139 |
GO:006076012 | Thyroid | ATC | positive regulation of response to cytokine stimulus | 33/6293 | 57/18723 | 1.43e-04 | 9.91e-04 | 33 |
GO:009730528 | Thyroid | ATC | response to alcohol | 113/6293 | 253/18723 | 1.53e-04 | 1.06e-03 | 113 |
GO:007252223 | Thyroid | ATC | purine-containing compound biosynthetic process | 92/6293 | 200/18723 | 1.74e-04 | 1.18e-03 | 92 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919N>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919G>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.2032N>C | p.Asp678His | p.D678H | P09874 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
PARP1 | SNV | Missense_Mutation | | c.2524G>A | p.Glu842Lys | p.E842K | P09874 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP1 | SNV | Missense_Mutation | novel | c.2971G>C | p.Val991Leu | p.V991L | P09874 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | novel | c.1102A>C | p.Thr368Pro | p.T368P | P09874 | protein_coding | tolerated(0.29) | benign(0.079) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.268N>A | p.Glu90Lys | p.E90K | P09874 | protein_coding | tolerated(0.09) | possibly_damaging(0.566) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Quinazolinedione derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 223366069 | RUCAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL1094636 | NIRAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CC-486 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | OLAPARIB | OLAPARIB | 28454547,25144364,26650448 |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Phthalazine ketone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | RUCAPARIB | RUCAPARIB | |